Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04128020
Title Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sherif Farag
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Azacitidine + Nivolumab

Nivolumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.